Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient
Author(s) -
YungYi Lee,
JuiHung Ko,
ChiaHung Wei,
WenHung Chung
Publication year - 2012
Publication title -
dermatologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.604
H-Index - 17
eISSN - 2223-330X
pISSN - 1027-8117
DOI - 10.1016/j.dsi.2012.06.005
Subject(s) - toxic epidermal necrolysis , medicine , etanercept , mucocutaneous zone , dermatology , human immunodeficiency virus (hiv) , adverse effect , skin biopsy , biopsy , immunology , pathology , tumor necrosis factor alpha , disease
Toxic epidermal necrolysis (TEN) is an uncommon and severe cutaneous adverse drug reaction that causes disseminated necrosis of epidermal cells and mucocutaneous detachment. Here, we report the case of a 32-year-old man with human immunodeficiency virus infection who presented with generalized violaceous macules and blister formation 4 days after the administration of mefenamic acid and amoxicillin for a dental procedure. Additional symptoms included oral ulcers and conjunctivitis. Results of skin biopsy were compatible with Stevens–Johnson syndrome (SJS). SJS progressed to TEN within 2 days. Etanercept treatment showed a dramatic improvement in the symptoms of mucocutaneous lesions. To our knowledge, this is the first report on the treatment of TEN using etanercept in a human immunodeficiency virus-positive patient
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom